PTJ
RAPT

Paul Tudor Jones’s RAPT Therapeutics RAPT Stock Holding History

Paul Tudor Jones’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,094
Closed -$150K – 2720
2024
Q1 		$150K Buy
+2,094
New +$291K ﹤0.01% 2072

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Paul Tudor Jones's RAPT Position: Q2 2024 in Review

Paul Tudor Jones sold out of RAPT Therapeutics (RAPT) in Q2 2024, closing a stake of 2,094 shares — an estimated $150K sold.

Paul Tudor Jones first reported a position in RAPT in Q1 2024 and held it in 1 quarter. The position peaked at $150K in Q1 2024. 103 funds tracked by Wall St. Rank hold RAPT as of Q2 2024.

  • Paul Tudor Jones reported no remaining RAPT Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Paul Tudor Jones sold 2,094 RAPT Therapeutics shares in Q2 2024, an estimated $150K.
  • Paul Tudor Jones first reported a position in RAPT Therapeutics in Q1 2024 and held it in 1 quarter.
  • Paul Tudor Jones's RAPT Therapeutics position peaked at $150K in Q1 2024.
  • 103 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2024.

Based on Tudor Investment Corp's 13F filing for Q2 2024, filed 14 Aug 2024.